Strides Pharma Science announced that the company and its wholly owned subsidiary, Strides Pharma Asia completed the sale to Mylan Laboratories and Mylan Institutional Inc. of Agila Specialties and Agila
Specialties Global respectively, pursuant to Sale and Purchase Agreements effective as of 27 February 2013 (gSPAsh) on 04 December 2013.
Mylan made claims against the General Claims Escrow which included a third]party claim that was subject to resolution under international arbitration. The claims in that arbitration were rejected in their entirety. Strides will receive ~ US$ 42 Mn towards full and final release of the General Claims Escrow immediately.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
